NASDAQ:ELGX - Endologix Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0.30 (1.20%)
Get New Endologix Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ELGX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ELGX

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Endologix in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for ELGX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Endologix. This rating has held steady since May 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/31/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/1/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/30/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/27/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/26/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/11/2020BTIG ResearchDowngradeBuy ➝ NeutralHigh
3/23/2020StephensLower Price TargetEqual Weight$3.00 ➝ $2.00Low
2/25/2020BTIG ResearchReiterated RatingBuy$6.00High
2/20/2020Piper SandlerLower Price Target$1.00Low
2/20/2020StephensLower Price TargetEqual Weight$7.00 ➝ $3.00High
8/9/2019Royal Bank of CanadaSet Price TargetHold$7.00High
4/1/2019Stifel NicolausSet Price TargetHold$7.00Low
2/26/2019BTIG ResearchReiterated RatingBuyLow
11/4/2018BTIG ResearchReiterated RatingBuyMedium
11/2/2018OppenheimerSet Price TargetHold$30.00Low
10/3/2018OppenheimerReiterated RatingHoldHigh
10/3/2018Piper Jaffray CompaniesLower Price TargetNeutral$30.00High
8/23/2018BTIG ResearchLower Price TargetBuy$40.00Medium
8/11/2018Stifel NicolausSet Price TargetHold$30.00High
8/10/2018BMO Capital MarketsReiterated RatingMarket Perform ➝ Hold$65.00 ➝ $40.00High
8/10/2018OppenheimerSet Price TargetHold$40.00High
8/10/2018Piper Jaffray CompaniesDowngradeOverweight ➝ NeutralHigh
5/21/2018Stifel NicolausBoost Price TargetHold ➝ Hold$45.00 ➝ $50.00High
5/3/2018OppenheimerSet Price TargetHold$50.00Low
2/22/2018OppenheimerSet Price TargetHold$50.00Low
1/2/2018JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightHigh
12/12/2017Piper Jaffray CompaniesReiterated RatingOverweight ➝ OverweightHigh
11/8/2017Stifel NicolausLower Price TargetHold$60.00 ➝ $55.00N/A
11/8/2017Royal Bank of CanadaLower Price TargetSector Perform$50.00 ➝ $40.00N/A
10/6/2017Stifel NicolausSet Price TargetHold$60.00N/A
10/3/2017Royal Bank of CanadaReiterated RatingHold$50.00High
8/3/2017OppenheimerSet Price TargetHold$50.00High
8/2/2017Stifel NicolausSet Price TargetHold$60.00High
7/31/2017Royal Bank of CanadaReiterated RatingHold$50.00Medium
6/5/2017Stifel NicolausReiterated RatingBuy$50.00 ➝ $55.00Medium
5/18/2017OppenheimerDowngradeOutperform ➝ Market Perform$60.00Medium
5/18/2017Royal Bank of CanadaReiterated RatingHoldMedium
5/18/2017BMO Capital MarketsReiterated RatingHold$50.00High
5/18/2017StephensDowngradeOverweight ➝ Equal Weight$60.00High
5/18/2017BTIG ResearchDowngradeBuy ➝ Neutral$70.00High
5/18/2017Stifel NicolausDowngradeBuy ➝ Hold$100.00 ➝ $55.00High
4/13/2017Royal Bank of CanadaReiterated RatingHold$80.00Low
4/11/2017BMO Capital MarketsReiterated RatingHold$70.00Low
4/5/2017OppenheimerReiterated RatingBuyHigh
3/22/2017OppenheimerReiterated RatingBuyLow
2/23/2017OppenheimerSet Price TargetBuy$100.00N/A
(Data available from 1/26/2017 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/29/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/28/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/27/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/26/2022

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Endologix logo
Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system. It also provides endovascular aneurysm sealing system (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, the company offers proximal aortic extensions and limb extensions, which allow physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. It sells its products through direct sales force, and a network of third party distributors and agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.03
Low: $0.02
High: $0.22

52 Week Range

Now: N/A

Volume

N/A

Average Volume

1,278,341 shs

Market Capitalization

$382,000.00

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.73

Frequently Asked Questions

What sell-side analysts currently cover shares of Endologix?

The following Wall Street analysts have issued stock ratings on Endologix in the last year:
View the latest analyst ratings for ELGX.

What is the current price target for Endologix?

0 Wall Street analysts have set twelve-month price targets for Endologix in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Endologix in the next year.
View the latest price targets for ELGX.

What is the current consensus analyst rating for Endologix?

Endologix currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ELGX.

How do I contact Endologix's investor relations team?

Endologix's physical mailing address is 2 MUSICK, IRVINE CA, 92618. The medical instruments supplier's listed phone number is 949-595-7200 and its investor relations email address is [email protected] The official website for Endologix is www.endologix.com.